









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on November 2022

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
nil				
2) New Requests				
Somatrogon (Ngenla®)	RED			Product rationalisation required by service for new patients
Pembrolizumab	RED			Renal Cell Carcinoma FOC scheme HUTH only
3) New formulations & extensions to use				
Octreotide subcutaneous injection	AMB 1			For use in palliative care gastro indications

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
4) Products considered by NICE				
TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner
TA824: Dexamethasone intravitreal implant for treating diabetic macular oedema	RED			The formulary will reflect the TAG – ICS is the responsible commissioner
TA825: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner
TA829: Upadacitinib for treating active ankylosing spondylitis	RED			The formulary will reflect the TAG – ICS is the responsible commissioner
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
None				

The following guidelines were presented to and approved at the November 2022 meeting of the APC:

- None this month

The following drug information leaflets were presented to and approved at the November 2022 meeting of the APC:

- None this month

The following shared care guidelines were presented to and approved at the November 2022 meeting of the APC:

- None this month

Other documents presented to and approved at the November 2022 meeting of the APC:

- Chapter 13 of joint formulary